ImmunoCellular Therapeutics (IMUC) Tops Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts IMUC Hot Sheet
Join SI Premium – FREE
ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05).
For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
